Statistiche di base
| CIK | 1416792 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Relypsa, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| August 13, 2019 |
RLYP / Relypsa, Inc. CT ORDER - - begin 644 filename1 M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#$O2VED'0O26UA9V5"+TEM86=E0R]);6%G94E=(#X^+TUE9&EA0F]X6R P(# @-C$R M(#2]#4R]$979I8V521T(^/B]486)S+U,O4W1R=6-T4&%R96YT M)RM66UOXS8,EZ@T' OMA J[-> M+-G#84 O36\9UG9H<\. |
|
| August 13, 2019 |
RLYP / Relypsa, Inc. CT ORDER - - begin 644 filename1 M)5!$1BTQ+C8-)>+CS],-"C0W(# @;V)J#3P\+TQI;F5A<>2/[\(Z!":AW'U@] M R,*^9^!<>E?@ # +$"@-"F5N9'-T7!E M+T]B:E-T;3X^T[:INL0TN&[O^X!\0E4. |
|
| September 17, 2018 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A #0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G (.)094P C$+ P<#%LP(# @-C$R(#7!E+T]B:E-T;3X^/[I[S/2P$"DR B(%% MP#RSQ> )#IR"B"+@#!AE =SCN=&OB/-?R11:O,80F,)+/NFBR!?J&S-E.5ABAFY%8>OZI\?]"&)Z7D3KG0A+.0+ JY;\' |
|
| February 14, 2017 |
RLYP / Relypsa, Inc. / JHL Capital Group LLC - 13G/A Passive Investment SC 13G/A 1 rlyp123116a1.htm 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relypsa, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 759531106 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2017 |
RLYP / Relypsa, Inc. / DELPHI VENTURES VII L P - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statemen |
|
| October 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION October 20, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES ACT OF 1933 Relypsa, Inc. |
|
| October 7, 2016 |
RLYP / Relypsa, Inc. / HIGHLAND CAPITAL MANAGEMENT FUND ADVISORS, L.P. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A (Rule 13d-102) (Amendment No. |
|
| September 19, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION September 19, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Relypsa, Inc. |
|
| September 12, 2016 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of Registrant as specified in its |
|
| September 6, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. |
|
| September 6, 2016 |
S-8 POS 1 d223345ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. 333-192441 Registration No. 333-202678 Registration No. 333-206163 Registration No. 333-209724 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-192441 POST-EFFECTIVE AMENDMENT |
|
| September 6, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. |
|
| September 6, 2016 |
S-8 POS As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. |
|
| September 6, 2016 |
As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. |
|
| September 6, 2016 |
POS AM As filed with the Securities and Exchange Commission on September 6, 2016 Registration No. |
|
| September 1, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| September 1, 2016 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION RELYPSA, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RELYPSA, INC. FIRST: The name of the corporation (the ?Corporation?) is Relypsa, Inc. SECOND: The address of the Corporation?s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of the Corporation?s registered agent at s |
|
| September 1, 2016 |
AMENDED AND RESTATED BYLAWS RELYPSA, INC. ARTICLE I - MEETINGS OF STOCKHOLDERS EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF RELYPSA, INC. ARTICLE I - MEETINGS OF STOCKHOLDERS Section 1.1 Annual Meetings. If required by applicable law, an annual meeting of stockholders shall be held for the election of directors at such date, time and place, if any, either within or without the State of Delaware, as may be designated by resolution of the Board of Directors from time to t |
|
| September 1, 2016 |
SC 14D9/A 1 d248675dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 5) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| September 1, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Offeror) (Names of Filing Persons (identify |
|
| September 1, 2016 |
Investor Relations, Galenica Group: Jörg Kneubühler, CFO EX-99.(A)(5)(H) 2 d222661dex99a5h.htm EX-99.(A)(5)(H) Exhibit (a)(5)(H) PRESS RELEASE Date 1 September 2016 Contact Investor Relations, Galenica Group: Jörg Kneubühler, CFO Media Relations, Galenica Group: Christina Hertig, Head Corporate Communications Media Relations, Vifor Pharma: Beatrix Benz, Head Global Communications & Public Affairs Subject Galenica announces Expiration of Cash Tender Offe |
|
| August 25, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Offeror) (Names of Filing Persons (identify |
|
| August 25, 2016 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 4) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number o |
|
| August 24, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Offeror) (Names of Filing Persons (identify |
|
| August 24, 2016 |
SC 14D9/A 1 d246691dsc14d9a.htm SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Secur |
|
| August 17, 2016 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number o |
|
| August 17, 2016 |
CORRESP 250 VESEY STREET • NEW YORK, NEW YORK 10281.1047 TELEPHONE: +1.212.326.3939 • FACSIMILE: +1.212.755.7306 DIRECT NUMBER: (212) 326-8319 [email protected] JP843204 August 17, 2016 Mr. Nicholas P. Panos Senior Special Counsel Securities and Exchange Commission Office of Mergers and Acquisitions 100 F Street, N.E. Washington, D.C. 20549-3628 Re: Relypsa, Inc. Schedule TO-T Filed August 4, |
|
| August 17, 2016 |
August 17, 2016 VIA EDGAR TRANSMISSION AND FEDERAL EXPRESS Nicholas P. Panos Senior Special Counsel 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Barcelona Moscow Beijing Munich Boston New Jersey Brussels New York Century City Orange County Chicago Paris Dubai Riyadh Düsseldorf Rome Frankfurt San Diego Hamburg San Francis |
|
| August 17, 2016 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Offeror) (Names of Filing Persons (identify |
|
| August 15, 2016 |
August 12, 2016 Via E-mail Mr. Oliver Kronenberg Group General Counsel Galenica AG Untermattweg 8-P.O. Box CH-3027 Bern, Switzerland Re: Relypsa, Inc. Schedule TO-T Filed August 4, 2016 Amendment No. 1 to Schedule TO-T Filed August 9, 2016 Filed by Vifor Pharma USA Inc. and Galenica AG File No. 005-87732 Dear Mr. Kronenberg: We have limited our review of the filing to those issues we have addresse |
|
| August 15, 2016 |
August 12, 2016 Via E-mail Mr. John A. Orwin President and Chief Executive Officer Relypsa, Inc. 100 Cardinal Way Redwood City, California 94063 Re: Relypsa, Inc. Schedule 14D-9 Filed August 4, 2016 Amendment No. 1 to Schedule 14D-9 Filed August 9, 2016 File No. 005-87732 Dear Mr. Orwin: We have limited our review of the filing to those issues we have addressed in our comments. In some of our comm |
|
| August 10, 2016 |
EX-24.1 2 poamontgomery.htm POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of Relypsa, Inc., a Delaware corporation (the "Company"), who is currently John A. Orwin, (ii) the Company's Chief Financial Officer, who is currently Kristine M. Ball, and (iii) the Company's General Counsel, who is currently Ronald |
|
| August 10, 2016 |
EX-24.1 2 poamontgomery.htm POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of (i) the Chief Executive Officer of Relypsa, Inc., a Delaware corporation (the "Company"), who is currently John A. Orwin, (ii) the Company's Chief Financial Officer, who is currently Kristine M. Ball, and (iii) the Company's General Counsel, who is currently Ronald |
|
| August 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number of Class of |
|
| August 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) RELYPSA, INC. (Name of Subject Company (issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Parent of Offeror) (Names of Filing Persons (identify |
|
| August 8, 2016 |
EX-99.1 2 d208127dex991.htm EX-99.1 EXHIBIT 99-1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common stock, par value $0.001 per share e, of Relypsa, Inc., a Delaware corpo |
|
| August 8, 2016 |
RLYP / Relypsa, Inc. / HIGHLAND CAPITAL MANAGEMENT FUND ADVISORS, L.P. - SC 13G Passive Investment SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Relypsa, Inc. |
|
| August 4, 2016 |
Relypsa 10-Q (Quarterly Report) rlyp-10q20160630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of regist |
|
| August 4, 2016 |
RELYPSA, INC. 100 Cardinal Way Redwood City, CA 94063 Exhibit (d)(4) RELYPSA, INC. 100 Cardinal Way Redwood City, CA 94063 May 8, 2016 Galenica Ltd. Untermattweg 8 3027 Bern Switzerland Confidentiality Agreement Ladies and Gentlemen: A. You have indicated your interest in a possible acquisition of Relypsa, Inc. (the ?Company?) by way of a merger, purchase of stock, purchase of assets or otherwise (a ?Potential Transaction?). The Company may from time |
|
| August 4, 2016 |
Exhibit (d)(2) T094(E) BILATERAL CDA BOTH PARTIES DISCLOSING CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (hereinafter referred to as the ?Agreement?) shall be effective as of the 6th day of May, 2014 (hereinafter referred to as the ?Effective Date?) and is entered into by and between Vifor Fresenius Medical Care Renal Pharma Ltd. |
|
| August 4, 2016 |
Amendment No. 1 to Manufacturing and Supply Agreement between Lanxess Corporation and Relypsa, Inc. Exhibit 10.2 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Amendment No. 1 to Manufacturing and Supply Agreement between Lanxess Corporation and Relypsa, Inc. This Amendment No. 1 to the Manufacturing and Supply Agreement (“Amendment No. 1” |
|
| August 4, 2016 |
EX-99.(a)(1)(E) Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RELYPSA, INC. at $32.00 Net Per Share by VIFOR PHARMA USA INC., an indirect wholly owned subsidiary of GALENICA AG THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK TIME, AT THE END OF THE DAY, WEDNESDAY, AUGUST 31, 2016, UNLESS THE OFFER IS EXTENDED. To Our Clients: Enclosed for |
|
| August 4, 2016 |
EX-99.(a)(1)(D) Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RELYPSA, INC. at $32.00 Net Per Share by VIFOR PHARMA USA INC., an indirect wholly owned subsidiary of GALENICA AG THE OFFER AND WITHDRAWAL RIGHTS EXPIRE AT 12:00 MIDNIGHT, NEW YORK TIME, AT THE END OF THE DAY ON WEDNESDAY, AUGUST 31, 2016, UNLESS THE OFFER IS EXTENDED. August 4, 2016 To Brokers, |
|
| August 4, 2016 |
EX-99.(A)(1)(C) 4 d148903dex99a1c.htm EX-99.(A)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY To Tender Shares of Common Stock of RELYPSA, INC. at $32.00 Net Per Share by VIFOR PHARMA USA INC., an indirect wholly owned subsidiary of GALENICA AG This form, or a substantially equivalent form, must be used to accept the Offer (as defined below) if certificates representing tendered Shares (as |
|
| August 4, 2016 |
EX-99.(a)(5)(F) Exhibit (a)(5)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase (as defined below), dated August 4, 2016, and the related Letter of Transmittal (as defined b |
|
| August 4, 2016 |
EX-99.(b) Facility Agreement Execution Copy Exhibit (b) CHF 1,450,000,000 MULTICURRENCY TERM FACILITY AGREEMENT dated 20 July 2016 for GALENICA AG as Original Guarantor arranged by CREDIT SUISSE AG as Arranger with CREDIT SUISSE AG acting as Agent Baker & McKenzie Zurich Holbeinstrasse 30, P.O.Box CH-8034 Zurich, Switzerland Facility Agreement Execution Copy CONTENTS Clause Page 1. Definitions and |
|
| August 4, 2016 |
EX-10.1 2 rlyp-ex101254.htm EX-10.1 Exhibit 10.1 CREDIT AGREEMENT Dated as of April 27, 2016 among RELYPSA, INC., as the Borrower, CERTAIN DOMESTIC SUBSIDIARIES OF THE BORROWER, as the Guarantors, CANTOR FITZGERALD SECURITIES, as the Administrative Agent and THE LENDERS FROM TIME TO TIME PARTY HERETO TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND ACCOUNTING TERMS 1 1.01 Defined Terms1 1.02 Other |
|
| August 4, 2016 |
Relypsa, Inc. 100 Cardinal Way Redwood City, CA 94063 Exhibit (a)(16) Relypsa, Inc. 100 Cardinal Way Redwood City, CA 94063 August 4, 2016 Dear Stockholder: We are pleased to inform you that, on July 20, 2016, Relypsa, Inc. (?Relypsa?) entered into a definitive Agreement and Plan of Merger (the ?Merger Agreement?) with Galenica AG (?Parent?) and Vifor Pharma USA Inc., an indirect wholly owned subsidiary of Parent (?Merger Sub?), pursuant to which Mer |
|
| August 4, 2016 |
EX-99.(A)(1)(A) 2 d148903dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) August 4, 2016 Offer to Purchase for Cash All Outstanding Shares of Common Stock of Relypsa, Inc. at $32.00 Net Per Share by Vifor Pharma USA Inc., an indirect wholly owned subsidiary of Galenica AG THE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 12:00 MIDNIGHT, NEW YORK TIME, AT THE END OF THE DAY ON WEDNESDA |
|
| August 4, 2016 |
Investor Relations, Galenica Group: Julien Vignot, Head Investor Relations EX-99.(A)(5)(G) 8 d148903dex99a5g.htm EX-99.(A)(5)(G) Exhibit (a)(5)(G) PRESS RELEASE Date 4 August 2016 Contact Investor Relations, Galenica Group: Julien Vignot, Head Investor Relations Media Relations, Galenica Group: Christina Hertig, Head Corporate Communications Media Relations, Vifor Pharma: Beatrix Benz, Head Global Communications & Public Affairs Subject Galenica commences Tender Offer fo |
|
| August 4, 2016 |
EX-99.(D)(3) 11 d148903dex99d3.htm EX-99.(D)(3) Exhibit (d)(3) AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT BETWEEN RELYPSA, INC. AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD. THIS AMENDMENT NO. 1 TO THE CONFIDENTIALITY AGREEMENT (“Amendment No. 1”) is made and entered into effective as of May 6, 2015 (the “Amendment No. 1 Effective Date”) by and between RELYPSA, INC., a Delaware corporation, |
|
| August 4, 2016 |
AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT BETWEEN RELYPSA, INC. AND GALENICA LTD. EX-99.(D)(5) 13 d148903dex99d5.htm EX-99.(D)(5) Exhibit (d)(5) AMENDMENT NO. 1 TO CONFIDENTIALITY AGREEMENT BETWEEN RELYPSA, INC. AND GALENICA LTD. THIS AMENDMENT NO. 1 TO THE CONFIDENTIALITY AGREEMENT (“Amendment No. 1”) is made and entered into effective as of May 11, 2016 (the “Amendment No. 1 Effective Date”) by and between RELYPSA, INC., a Delaware corporation, located at 100 Cardinal Way, Re |
|
| August 4, 2016 |
SC TO-T 1 d148903dsctot.htm SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) An Indirect Wholly Owned Subsidiary of GALENICA AG (Parent of Offeror) (Names of Filing |
|
| August 4, 2016 |
SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE Exhibit 10.3 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. SETTLEMENT AGREEMENT AND MUTUAL GENERAL RELEASE This Settlement Agreement and Mutual General Release (this "Agreement") is made and entered into as of June 21, 2016 (the “Effective |
|
| August 4, 2016 |
SC 14D9 1 d343483dsc14d9.htm SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Clas |
|
| August 4, 2016 |
EX-99.(A)(1)(B) 3 d148903dex99a1b.htm EX-99.(A)(1)(B) Exhibit (a)(1)(B) Letter of Transmittal to Offer to Purchase for Cash All Outstanding Shares of Common Stock of Relypsa, Inc. at $32.00 Net Per Share by Vifor Pharma USA Inc., an indirect wholly owned subsidiary of Galenica AG The undersigned represents that I (we) have full authority to surrender without restriction the certificate(s) listed b |
|
| July 28, 2016 |
EX-99.1 2 ss4640ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated July 28, 2016 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, |
|
| July 28, 2016 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 9 Activist Investment SC 13D/A 1 ss4640sc13da.htm AMENDMENT NO. 9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 1 |
|
| July 26, 2016 |
EX-99.1 2 ss4294ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated July 26, 2016 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, |
|
| July 26, 2016 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 8 Activist Investment SC 13D/A 1 ss4294sc13da.htm AMENDMENT NO. 8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 1 |
|
| July 25, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 RELYPSA, INC. (Name of Subject Company (Issuer)) VIFOR PHARMA USA INC. (Offeror) A Wholly-Owned Subsidiary of GALENICA AG (Ultimate Parent Entity of Offeror) (Names of Filing Persons (identifying status as offeror, issu |
|
| July 25, 2016 |
EX-99.1 Exhibit 99.1 EDITED TRANSCRIPT GALNA.S ? Galenica AG To Acquire Relypsa To Strengthen Its Business Unit Vifor Pharma M&A Call EVENT DATE/TIME: JULY 21, 2016 / 12:00PM GMT 1 JULY 21, 2016 / 12:00PM GMT, GALNA.S ? Galenica AG To Acquire Relypsa To Strengthen Its Business Unit Vifor Pharma M&A Call CORPORATE PARTICIPANTS Jorg Kneubuhler Galenica Group - CFO, Galenica Group & CEO, Galenica San |
|
| July 21, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number of Class of Securitie |
|
| July 21, 2016 |
EX-99.4 Exhibit 99.4 EXHIBIT 99.4 Trust in excellence Colin Bond CFO Vifor Pharma Vifor Pharma, a company of the Galenica Group Vifor Pharma aims to become a successful, stand-alone, global speciality pharma company 21/07/2016? ? Vifor Pharma 2 VIFOR PHARMA GALENICA CURRENTLY PART OF THE GALENLCA GROUP SWITZERLAND HEADQUARTERS IN ZURICH, SWITZERLAND REASERACH & DEVELOPMENT FACILITIES IN ST. Gallen |
|
| July 21, 2016 |
EX-99.3 Exhibit 99.3 GALENICA Galenica to acquire Relypsa Vifor Pharma & relypsa Conference Call, July 21, 2016, 2 p.m. CET The Galenica Group - Excellence in the healthcare market GALENICA Agenda and speakers Etienne Jornod Executive Chairman Galenica Group J?rg Kneub?hler CFO Galenica Group & CEO Galenica Sant? Gianni Zampieri Vice-CEO Vifor Pharma Christoph Springer Head BD & Licensing & Deputy |
|
| July 21, 2016 |
EX-99.2 3 d219698dex992.htm EX-99.2 Exhibit 99.2 NEWS RELEASE Relypsa Contact Charlotte Arnold, Vice President, Corporate Communications and Investor Relations Tel.: +1 650 421 9352 E-mail: [email protected] Galenica Contacts Galenica Media Relations: Galenica Investor Relations: Christina Hertig, Head Corporate Communications Tel.: +41 58 852 85 17 E-mail: [email protected] Jörg Kneubühler, Chief F |
|
| July 21, 2016 |
Galenica and Relypsa announce agreement for Galenica to acquire Relypsa. EX-99.1 Exhibit 99.1 PRESS RELEASE Date 21 July 2016 Contact Investor Relations, Galenica Group: J?rg Kneub?hler, CFO Media Relations, Galenica Group: Christina Hertig, Head Corporate Communications Media Relations, Vifor Pharma: Beatrix Benz, Head Global Communications & Public Affairs Media & Investor Relations, Relypsa: Charlotte Arnold, Vice President, Corporate Communications & Investor Relat |
|
| July 21, 2016 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company (issuer)) VIFOR PHARMA USA INC. (Offeror) A Wholly-Owned Subsidiary of GALENICA AG (Ultimate Parent Entity of Offeror) (Names of Filing Persons (identifying status as offer |
|
| July 21, 2016 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 RELYPSA, INC. (Name of Subject Company) RELYPSA, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number of Class of Securitie |
|
| July 21, 2016 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Relypsa Contact Charlotte Arnold, Vice President, Corporate Communications and Investor Relations Tel.: +1 650 421 9352 E-mail: [email protected] Galenica Contacts Galenica Media Relations: Galenica Investor Relations: Christina Hertig, Head Corporate Communications Tel.: +41 58 852 85 17 E-mail: [email protected] J?rg Kneub?hler, Chief Financial Officer Tel.: +41 5 |
|
| July 21, 2016 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER by and among GALENICA AG, VIFOR PHARMA USA INC. and RELYPSA, INC. Dated as of July 20, 2016 TABLE OF CONTENTS Page Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 Article II THE MERGER 6 2.1 The Merger 6 2.2 The Effective Time 6 2.3 The Closing 6 2.4 Effect of the Merger 6 2.5 Certificate of Incorporation and Bylaws 6 2. |
|
| July 21, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| July 11, 2016 |
8-K 1 d224165d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorpor |
|
| June 27, 2016 |
Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION 15 June 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Relypsa, Inc. |
|
| June 15, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 3, 2016 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated June 3, 2016 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| June 3, 2016 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 75931106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address |
|
| May 27, 2016 |
RLYP / Relypsa, Inc. / Flynn James E Passive Investment SC 13G 1 e615097sc13g-relypsa.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) May 17, 2016 (Date of |
|
| May 16, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2016 |
Relypsa 10-Q (Quarterly Report) rlyp-10q20160331.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of regis |
|
| May 4, 2016 |
Relypsa FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| May 4, 2016 |
Exhibit 99.1 Contact: Charlotte Arnold Vice President, Corporate Communications and Investor Relations 650-421-9352 [email protected] Relypsa Reports First Quarter 2016 Financial Results Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT REDWOOD CITY, Calif., May 4, 2016 Relypsa, Inc. (NASDAQ: RLYP), a biopharmaceutical company, today reported financial r |
|
| May 4, 2016 |
Amendment No. 1 to Manufacturing and Supply Agreement EX-10.2 3 rlyp-ex102421.htm EX-10.2 Exhibit 10.2 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Amendment No. 1 to Manufacturing and Supply Agreement This Amendment No. 1 to the Manufacturing and Supply Agreement (“Amendment No. 1”) is made |
|
| May 4, 2016 |
ADDENDUM 1 Additional MFA Services Exhibit 10.1 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. ADDENDUM 1 Additional MFA Services This Addendum 1 dated February 11th, 2015 ("Addendum 1 Effective Date") describes certain services to be managed by DPx Fine Chemicals Austria Gmb |
|
| May 3, 2016 |
8-K 1 d190908d8k.htm FROM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorpo |
|
| May 3, 2016 |
EX-4.1 Exhibit 4.1 THIS COMMON STOCK PURCHASE WARRANT AND THE SHARES THAT MAY BE PURCHASED HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS OF ANY STATE. THIS COMMON STOCK PURCHASE WARRANT HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND NOT WITH A VIEW TO DISTRIBUTION, AND THIS COMMON STOCK PURCHASE WARRANT AND THE SHARES THAT MAY BE PURCHASED HEREUNDE |
|
| April 28, 2016 |
Relypsa DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2016 |
Relypsa DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 11, 2016 |
RLYP / Relypsa, Inc. / JANUS CAPITAL MANAGEMENT LLC - RLYP SC13GA Passive Investment SC 13G/A 1 rlyp4102016.txt RLYP SC13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: RELYPSA, INC. Title of Class of Securities: Common Stock CUSIP Number: 759531106 Date of Event Which Requires Filing of this Statement: 3/31/2016 Check the appropriate box to designate the rule pursua |
|
| March 15, 2016 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 11, 2016 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fi |
|
| February 25, 2016 |
S-8 1 d116696ds8.htm S-8 As filed with the Securities and Exchange Commission on February 25, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Relypsa, Inc. (Exact name of registrant as specified in its charter) Delaware 26-0893742 (State or other jurisdiction of incorporation or orga |
|
| February 25, 2016 |
10-K 1 rlyp-10k20151231.htm 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name o |
|
| February 25, 2016 |
STATEMENT REGARDING THE COMPUTATION OF RATIOS Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS Our earnings are inadequate to cover combined fixed charges and preference dividends. The following table sets forth the dollar amount of the coverage deficiency (in thousands) for the periods indicated. Year Ended December 31, 2015 2014 2013(1) 2012(2) 2011 EARNINGS: Net loss $ (178,716 ) $ (79,888 ) $ (73,845 ) $ (43,725 ) $ (25,823 ) Pl |
|
| February 25, 2016 |
FIFTH AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.4(f) FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of December 17, 2015, by and between Silicon Valley Bank (“Bank”) and Relypsa, Inc., a Delaware corporation (“Borrower”), whose address is 100 Cardinal Way, Redwood City, California 94063. Recitals A. Bank and Borrower have entered into that certa |
|
| February 25, 2016 |
Exhibit 10.15(a) RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN (as amended by the Board on December 10, 2015) ARTICLE 1. PURPOSE The purpose of the Relypsa, Inc. 2014 Employment Commencement Incentive Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Relypsa, Inc. (the “Company”) by linking the individual interests of the Eligi |
|
| February 24, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| February 24, 2016 |
EX-99.1 Exhibit 99.1 Contact: Charlotte Arnold Vice President, Corporate Communications 650-421-9352 [email protected] Relypsa Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Other Corporate Updates ? Relypsa reports encouraging initial demand for Veltassa ? Veltassa added to CMS 2016 Formulary Reference File and agreements signed with Express Scripts and CVS Caremark, the t |
|
| February 16, 2016 |
RLYP / Relypsa, Inc. / JANUS CAPITAL MANAGEMENT LLC - RLYP SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: RELYPSA, INC. Title of Class of Securities: Common Stock CUSIP Number: 759531106 Date of Event Which Requires Filing of this Statement: 12/31/2015 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X |
|
| February 5, 2016 |
Acceleration Request Relypsa, Inc. 100 Cardinal Way Redwood City, CA 94063 January 5, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Irene Paik Suzanne Hayes Re: Relypsa, Inc. Registration Statement on Form S-3 (Registration No. 333-207806) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the |
|
| January 28, 2016 |
RLYP / Relypsa, Inc. / BlackRock Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) RELYPSA INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 759531106 - (CUSIP Number) December 31, 2015 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |
|
| January 25, 2016 |
Relypsa Form 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission |
|
| January 25, 2016 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2016 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission |
|
| January 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 6, 2016 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Relypsa, Inc. |
|
| January 5, 2016 |
Acceleration Request Relypsa, Inc. 100 Cardinal Way Redwood City, CA 94063 January 5, 2016 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Irene Paik Suzanne Hayes Re: Relypsa, Inc. Registration Statement on Form S-3 (Registration No. 333-207806) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the |
|
| January 5, 2016 |
Relypsa Form 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36 |
|
| January 5, 2016 |
DETAILING AGREEMENT sanofi-aventis US LLC Relypsa, Inc. Dated as of August 10, 2015 EX-10.2 Exhibit 10.2 EXECUTION VERSION [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. DETAILING AGREEMENT between sanofi-aventis US LLC and Relypsa, Inc. Dated as of August 10, 2015 EXECUTION VERSION Table of Contents 1. DEFINITIONS 1 2. GOV |
|
| January 5, 2016 |
RLYP / Relypsa, Inc. 10-Q/A - Quarterly Report - FORM 10-Q/A Form 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Nu |
|
| December 24, 2015 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.6)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address |
|
| December 24, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated December 24, 2015 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| December 22, 2015 |
FIFTH AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.1 FIFTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FIFTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this ?Amendment?) is entered into as of December , 2015, by and among OXFORD FINANCE LLC (?Oxford?) as collateral agent (in such capacity, ?Collateral Agent?), the Lenders listed on Schedule 1.1 of the Loan Agreement or otherwise a party thereto from |
|
| December 22, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 d107047d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of inco |
|
| December 22, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| December 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 14, 2015 |
RLYP / Relypsa, Inc. / JHL Capital Group LLC - SCHEDULE 13G HOLDINGS REPORT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 16, 2015 |
Mail Stop 4720 November 16, 2015 Via E-mail John A. Orwin President and Chief Executive Officer Relypsa, Inc. 100 Cardinal Way Redwood City, CA 94063 Re: Relypsa, Inc. Registration Statement on Form S-3 Filed November 4, 2015 File No. 333-207806 Dear Mr. Orwin: We have limited our review of your registration statement to consideration of your pending request for confidential treatment. Please be a |
|
| November 4, 2015 |
EX-25.1 Exhibit 25.1 File No. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-148645 |
|
| November 4, 2015 |
EX-10.2 3 rlyp-ex102513.htm EX-10.2 Exhibit 10.2 EXECUTION VERSION [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. DETAILING AGREEMENT between sanofi-aventis US LLC and Relypsa, Inc. Dated as of August 10, 2015 EXECUTION VERSION Table of Cont |
|
| November 4, 2015 |
EX-4.4 Exhibit 4.4 Relypsa, Inc. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Section 1.2. Other Definitions. 4 Section 1.3. Incorporation by Reference of Trust Indenture Act. 5 Section 1.4. Rules of Construction. 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuab |
|
| November 4, 2015 |
FOURTH AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.3 4 rlyp-ex103512.htm EX-10.3 Exhibit 10.3 FOURTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 1st day of October, 2015, by and among OXFORD FINANCE LLC (“Oxford”) as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of t |
|
| November 4, 2015 |
Table of Contents As filed with the Securities and Exchange Commission on November 4, 2015 Registration No. |
|
| November 4, 2015 |
EX-1.2 Exhibit 1.2 RELYPSA, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement November 4, 2015 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Relypsa, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance and Sal |
|
| November 4, 2015 |
Table of Contents As filed with the Securities and Exchange Commission on November 4, 2015 Registration No. |
|
| November 4, 2015 |
FOURTH AMENDMENT LOAN AND SECURITY AGREEMENT EX-10.4 5 rlyp-ex104514.htm EX-10.4 Exhibit 10.4 FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into this 1st day of October, 2015, by and between Silicon Valley Bank (“Bank”) and Relypsa, Inc., a Delaware corporation (“Borrower”), whose address is 100 Cardinal Way, Redwood City, California 94063. Recitals A. Bank |
|
| November 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 rlyp-10q20150930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exa |
|
| November 4, 2015 |
Relypsa Announces Third Quarter 2015 Financial Results EX-99.1 Exhibit 99.1 Contact: Charlotte Arnold Vice President, Corporate Communications 650-421-9352 [email protected] Relypsa Announces Third Quarter 2015 Financial Results REDWOOD CITY, Calif., November 4, 2015 ? Relypsa, Inc. (NASDAQ: RLYP), a biopharmaceutical company, today reported financial results for the quarter ended September 30, 2015 and recent business highlights. ?We are very excited th |
|
| November 4, 2015 |
STATEMENT REGARDING THE COMPUTATION OF RATIOS EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS Our earnings are inadequate to cover combined fixed charges and preference dividends. The following table sets forth the dollar amount of the coverage deficiency (in thousands) for the periods indicated. Year Ended December 31, Nine Months Ended September 30, 2015 2014 2013(1) 2012(2) 2011 EARNINGS: Net loss $ (79,888 ) $ (73,845 ) |
|
| November 4, 2015 |
EX-10.1 2 rlyp-ex101543.htm EX-10.1 Exhibit 10.1 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Confidential Execution Copy LICENSE AGREEMENT This License Agreement (the “Agreement”) is effective as of August 10, 2015 (the “Effective Date”) |
|
| November 4, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| November 4, 2015 |
Relypsa Form 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| October 30, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated October 30, 2015 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| October 30, 2015 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO.5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addres |
|
| October 22, 2015 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2015 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission |
|
| August 12, 2015 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2015 |
Form S-8 As filed with the Securities and Exchange Commission on August 6, 2015 Registration No. |
|
| August 6, 2015 |
RELYPSA ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 Contact: Charlotte Arnold Vice President, Corporate Communications 650-421-9352 [email protected] RELYPSA ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS REDWOOD CITY, Calif., August 6, 2015 ? Relypsa, Inc. (NASDAQ: RLYP), a biopharmaceutical company, today reported financial results for the quarter ended June 30, 2015. Net loss for the second quarter 2015 was $39.3 million, or $ |
|
| August 6, 2015 |
EX-10.1 2 rlyp-ex101420.htm EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of the 10th day of July, 2015, by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and RELYPSA, INC., a Delaware corporation (“Tenant”). r e c i t a l s : A.Landlord and Tenant entered into that certain Lease |
|
| August 6, 2015 |
EX-10.2(A) 3 rlyp-ex102a421.htm EX-10.2(A) Exhibit 10.2(a) RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN (as amended by the Board on July 8, 2015) ARTICLE 1. PURPOSE The purpose of the Relypsa, Inc. 2014 Employment Commencement Incentive Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Relypsa, Inc. (the “Company”) by linking |
|
| August 6, 2015 |
RELYPSA, inc. 2014 Employment commencement incentive PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE EX-10.2(B) 4 rlyp-ex102b422.htm EX-10.2(B) Exhibit 10.2(b) RELYPSA, inc. 2014 Employment commencement incentive PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Relypsa, Inc., a Delaware corporation, (the “Company”), pursuant to its 2014 Employment Commencement Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restrict |
|
| August 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 rlyp-10q20150630.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact na |
|
| August 6, 2015 |
Relypsa FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission F |
|
| July 27, 2015 |
CUSIP NO. 759531106 13D Page 1 of 14 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 5)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Paul Stone 5AM Ventures III, L |
|
| June 9, 2015 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF RELYPSA, INC. (a Delaware corporation) (As amended on June 4, 2015) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 AD |
|
| June 9, 2015 |
Relypsa FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 27, 2015 |
RLYP / Relypsa, Inc. / CITADEL ADVISORS LLC - SCHEDULE 13G Passive Investment SC 13G 1 v411592sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Relypsa, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 759531106 (CUSIP Number) May 18, 2015 Date |
|
| May 27, 2015 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Relypsa, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned |
|
| May 20, 2015 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment SC 13D/A 1 ss430957sc13da.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.4)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY |
|
| May 20, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated May 20, 2015 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| May 7, 2015 |
Relypsa 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 7, 2015 |
RELYPSA ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS EX-99.1 2 d924958dex991.htm EX-99.1 Exhibit 99.1 Contact: Alex Dobbin Associate Director, Investor Relations 650-421-9687 [email protected] RELYPSA ANNOUNCES FIRST QUARTER 2015 FINANCIAL RESULTS REDWOOD CITY, Calif., May 7, 2015 — Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2015. Net loss for the first quarter 2015 was $2 |
|
| May 7, 2015 |
CONSENT, RELEASE AND THIRD AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.1 CONSENT, RELEASE AND THIRD AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This CONSENT, RELEASE AND THIRD AMENDMENT to Amended and Restated Loan and Security Agreement (this “Consent”) is entered into this 30th day of January, 2015, by and among OXFORD FINANCE LLC (“Oxford”) as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 o |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 rlyp-10q20150331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact n |
|
| May 7, 2015 |
CONSENT, RELEASE AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.2 CONSENT, RELEASE AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT, RELEASE AND THIRD AMENDMENT to Loan and Security Agreement (this ?Consent?) is entered into this 30th day of January, 2015, by and between Silicon Valley Bank (?Bank?) and Relypsa, Inc., a Delaware corporation (?Borrower?) whose address is 700 Saginaw Drive, Redwood City, CA 94063. Recitals A. Bank and B |
|
| May 7, 2015 |
Exhibit 4.4 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTAN |
|
| May 7, 2015 |
RELYPSA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Exhibit 10.3 RELYPSA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the ?Board?) of Relypsa, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?), which was adopted pursuant to the Board?s resolutions on June 6, 2013, and amended pursuant to t |
|
| April 22, 2015 |
Relypsa DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 22, 2015 |
Relypsa DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 27, 2015 |
RLYP / Relypsa, Inc. / 5AM VENTURES III, L.P. - SC 13D/A Activist Investment CUSIP NO. 759531106 13D Page 1 of 12 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Paul Stone 5AM Ventures III, L |
|
| March 12, 2015 |
RELYPSA, INC. EMPLOYMENT AGREEMENT Exhibit 10.23 RELYPSA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Stephen D. Harrison, M.A., Ph.D. (?Executive?) and Relypsa, Inc. (the ?Company?) (together referred to herein as the ?Parties?), effective as of December 15, 2014 (the ?Effective Date?). This Agreement supersedes in its entirety that certain employment letter agreeme |
|
| March 12, 2015 |
RELYPSA, INC. EMPLOYMENT AGREEMENT Exhibit 10.22 RELYPSA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Scott Garland (?Executive?) and Relypsa, Inc. (the ?Company?) (together referred to herein as the ?Parties?), effective as of October 31, 2014 (the ?Effective Date?). This Agreement supersedes in its entirety that certain employment letter agreement dated as of Septe |
|
| March 12, 2015 |
S-8 1 d888692ds8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 11, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Relypsa, Inc. (Exact name of registrant as specified in its charter) Delaware 26-0893742 (State or other jurisdiction of incorporation or or |
|
| March 12, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of registrant as specified in its |
|
| March 11, 2015 |
RELYPSA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 Contact: Alex Dobbin Associate Director, Investor Relations 650-421-6879 [email protected] RELYPSA ANNOUNCES FOURTH QUARTER AND FULL YEAR 2014 FINANCIAL RESULTS REDWOOD CITY, Calif., March 11, 2014 ? Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014. Cash, cash equivalents and short- |
|
| March 11, 2015 |
Relypsa 8-K (Current Report/Significant Event) 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File N |
|
| March 6, 2015 |
EXHIBIT 2 FORM OF LOCK-UP LETTER RELYPSA, INC. LOCK-UP AGREEMENT , 2015 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated 1 Bryant Park New York, NY 10036 c/o Cowen and Company, LLC 599 Lexington Avenue, 27th Floor New York |
|
| March 6, 2015 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Addres |
|
| March 6, 2015 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated March 6, 2015 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| March 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION March 4, 2015 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Relypsa, Inc. |
|
| March 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36 |
|
| March 3, 2015 |
Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2015 |
Exhibit 10.1 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (?Agreement?) is made effective as of August 15, 2014 by and among Relypsa Inc., having its principal place of business at 700 Saginaw Drive, |
|
| March 3, 2015 |
3,900,000 Shares RELYPSA, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 Execution Version 3,900,000 Shares RELYPSA, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT February 25, 2015 February 25, 2015 Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated 1 Bry |
|
| February 26, 2015 |
Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| February 24, 2015 |
Subject to completion, dated February 24, 2015. Preliminary Prospectus Supplement Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| February 18, 2015 |
RLYP / Relypsa, Inc. / JANUS CAPITAL MANAGEMENT LLC - RLYP 12.31.14 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: * Name of Issuer: RELYPSA, INC. Title of Class of Securities: Common Stock CUSIP Number: 759531106 Date of Event Which Requires Filing of this Statement: 12/31/2014 Check the appropriate box to designate the rule pursuant to which this Schedule is filed. [X] |
|
| February 17, 2015 |
RLYP / Relypsa, Inc. / New Leaf Ventures I, L.p. - SC 13G/A Passive Investment SC 13G/A 1 d871787dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Relypsa, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 759531106 (CUSIP Number) Dece |
|
| February 11, 2015 |
RLYP / Relypsa, Inc. / DELPHI VENTURES VII L P - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statemen |
|
| February 6, 2015 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| February 6, 2015 |
RLYP / Relypsa, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Relypsa Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Calendar Year 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| January 28, 2015 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2015 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| December 15, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| December 12, 2014 |
RLYP / Relypsa, Inc. / 5AM VENTURES III, L.P. - SC 13D/A Activist Investment CUSIP NO. 759531106 13D Page 1 of 13 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Sc 13d/a Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Paul Stone 5AM Ventur |
|
| December 4, 2014 |
EX-25.1 Exhibit 25.1 File No. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE x CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-148645 |
|
| December 4, 2014 |
RLYP / Relypsa, Inc. S-3 - - S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on December 4, 2014 Registration No. |
|
| December 4, 2014 |
EX-1.2 Exhibit 1.2 Execution Version RELYPSA, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement December 4, 2014 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Relypsa, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1 |
|
| December 4, 2014 |
EX-4.4 Exhibit 4.4 Relypsa, Inc. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable i |
|
| December 4, 2014 |
STATEMENT REGARDING THE COMPUTATION OF RATIOS EX-12.1 Exhibit 12.1 STATEMENT REGARDING THE COMPUTATION OF RATIOS Our earnings are inadequate to cover combined fixed charges and preference dividends. The following table sets forth the dollar amount of the coverage deficiency (in thousands) for the periods indicated. Year Ended December 31, Nine Months Ended September 30, 2013(1) 2012(2) 2011 2014 EARNINGS: Net loss $ (73,845 ) $ (43,725 ) $ (2 |
|
| November 10, 2014 |
Exhibit 10.4 October 28, 2014 Relypsa, Inc. 5301 Patrick Henry Drive Santa Clara, CA 95054 Dear Sir or Madam: Reference is made to the Amended and Restated Intellectual Property License and Assignment Agreement dated November 23, 2009 between Ilypsa, Inc. and Relypsa, Inc. (the ?Agreement?). Capitalized terms used but not defined herein shall have the same meanings as assigned to such terms in the |
|
| November 10, 2014 |
CONSENT AND SECOND AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT Exhibit 10.2 CONSENT AND SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS CONSENT AND SECOND AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of October 24, 2014, by and among OXFORD FINANCE LLC (“Oxford”) as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement o |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of registrant as specifie |
|
| November 10, 2014 |
Exhibit 10.1 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (?Agreement?) is made effective as of August 15, 2014 by and among Relypsa Inc., having its principal place of business at 700 Saginaw Drive, |
|
| November 10, 2014 |
RELYPSA ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS EX-99.1 Exhibit 99.1 Contact: Sylvia Wheeler VP, Investor Relations & Corporate Affairs 650-421-9504 [email protected] RELYPSA ANNOUNCES THIRD QUARTER 2014 FINANCIAL RESULTS REDWOOD CITY, Calif., November 10, 2014 — Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2014. Net loss for the third quarter 2014 was $19.4 m |
|
| November 10, 2014 |
CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.3 CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND SECOND AMENDMENT to Loan and Security Agreement (this ?Consent?) is entered into as of October 24, 2014, by and between Silicon Valley Bank (?Bank?) and Relypsa, Inc., a Delaware corporation (?Borrower?) whose address is 700 Saginaw Drive, Redwood City, California 94063. RECITALS A. Bank and Borrower have ent |
|
| October 22, 2014 |
8-K 1 d809335d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporat |
|
| October 14, 2014 |
RLYP / Relypsa, Inc. CT ORDER - - begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,B]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``+VPRH@!&(61@X&I#% MF*&8@:&1@9N!9IS`U2E2"=41QM8%X/R%PB?D14@P`#WE08A#0IE;F1S=')E M86T-96YD;V)J#3$Q(#`@;V)J#3P\+TUE=&%D871A(#(@,"!2 |
|
| September 25, 2014 |
8-K 1 d794636d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorpor |
|
| September 17, 2014 |
RLYP / Relypsa, Inc. / 5AM VENTURES III, L.P. - SC 13D/A Activist Investment SC 13D/A 1 v389381sc13d-a.htm SC 13D/A CUSIP NO. 759531106 13D Page 1 of 12 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP |
|
| September 9, 2014 |
Entry into a Material Definitive Agreement Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commissio |
|
| September 3, 2014 |
RLYP / Relypsa, Inc. / 5AM VENTURES III, L.P. - SC 13D/A Activist Investment CUSIP NO. 759531106 13D Page 1 of 13 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Paul Stone 5AM Ventures III, L |
|
| August 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.2)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739-6400 (Name, Address |
|
| August 19, 2014 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated August 19, 2014 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| August 11, 2014 |
MANUFACTURING AND SUPPLY AGREEMENT [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. |
|
| August 11, 2014 |
RELYPSA, INC. FIRST AMENDMENT TO OFFER LETTER AGREEMENT JOHN A. ORWIN EX-10 5 rlyp-ex1020140630372.htm EX-10.8 Exhibit 10.8 RELYPSA, INC. FIRST AMENDMENT TO OFFER LETTER AGREEMENT JOHN A. ORWIN This FIRST AMENDMENT TO OFFER LETTER AGREEMENT (this “Amendment”) is entered into effective as of August 8, 2014, by and between RELYPSA, INC. (the “Company”) and JOHN A. ORWIN (“Executive”) (collectively, the “Parties”). RECITAL: WHEREAS, the Parties entered into that certai |
|
| August 11, 2014 |
EX-99.1 2 d770319dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Contact: Sylvia Wheeler VP, Investor Relations & Corporate Affairs 650-421-9504 [email protected] Relypsa Announces Second Quarter 2014 Financial Results — Company Updates Plans for NDA Submission to Early Q4 2014; Continues to Expect Approval 2H 2015 — REDWOOD CITY, Calif., August 11, 2014 — Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutic |
|
| August 11, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| August 11, 2014 |
RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. Exhibit 10.6 RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the Relypsa, Inc. 2014 Employment Commencement Incentive Plan (as it may be amended from time to time, the ?Plan?) is to promote the success and enhance the value of Relypsa, Inc. (the ?Company?) by linking the individual interests of the Eligible Participants to those of the Company?s stockhol |
|
| August 11, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of registrant as specified in |
|
| August 11, 2014 |
RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION GRANT NOTICE EX-10 4 rlyp-ex1020140630373.htm EX-10.7 Exhibit 10.7 RELYPSA, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION GRANT NOTICE Relypsa, Inc., a Delaware corporation, (the “Company”), pursuant to its 2014 Employment Commencement Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of s |
|
| July 31, 2014 |
RLYP / Relypsa, Inc. / 5AM VENTURES III, L.P. - SC 13D Activist Investment CUSIP NO. 759531106 13D Page 1 of 20 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Relypsa, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Paul Stone 5AM Ventures III, L. |
|
| July 1, 2014 |
EX-10.1 Exhibit 10.1 BRITANNIA SEAPORT CENTRE LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and RELYPSA, INC., a Delaware corporation (“Tenant”). SUMMARY OF BASIC LEASE INFORMATION TERMSOF LEASE DESCRIPTI |
|
| July 1, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fi |
|
| July 1, 2014 |
CONSENT AND FIRST AMENDMENT AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.2 Exhibit 10.2 CONSENT AND FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS CONSENT AND FIRST AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of June 26, 2014, by and among OXFORD FINANCE LLC (“Oxford”) as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreemen |
|
| June 24, 2014 |
Submission of Matters to a Vote of Security Holders - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| June 2, 2014 |
AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT EX-10.1 Exhibit 10.1 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT THIS AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of May 30, 2014 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, |
|
| June 2, 2014 |
EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND |
|
| June 2, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Num |
|
| May 20, 2014 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 12, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File |
|
| May 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36184 RELYPSA, INC. (Exact name of registrant as specified in |
|
| May 7, 2014 |
Relypsa Announces First Quarter 2014 Financial Results EX-99.1 Exhibit 99.1 NEWS RELEASE Contact: Sylvia Wheeler VP, Investor Relations & Corporate Affairs 650-421-9504 [email protected] Relypsa Announces First Quarter 2014 Financial Results REDWOOD CITY, Calif., May 7, 2014 – Relypsa, Inc. (Nasdaq: RLYP), a biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2014. Net loss for the first quarter 2014 was $16. |
|
| April 30, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 30, 2014 |
EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (“Amendment”) is made and entered into as of April 24, 2014, by and between HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (“Landlord”), and RELYPSA, INC., a Delaware corporation (“Tenant”). R E C I T A L S : A. Landlord and Tenant are parties to that certain Lease dated September 7, 2012, (the “Lease”), pu |
|
| April 28, 2014 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 28, 2014 |
- DEFINITIVE NOTICE AND PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 17, 2014 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13D, dated April 17, 2014 (the “Schedule 13D”), with respect to the Common Stock of Relypsa, Inc. |
|
| April 17, 2014 |
RLYP / Relypsa, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 TO SCHEDULE 13D Activist Investment SC 13D/A 1 ss210340sc13da.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* RELYPSA, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 759531106 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP IV LLC Samuel D. Isaly 601 Lexington Avenue, 54th Fl |
|
| April 16, 2014 |
Financial Statements and Exhibits, Other Events Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2014 RELYPSA, INC. (Exact name of registrant as specified in its charter) Delaware 001-36184 26-0893742 (State or other jurisdiction of incorporation) (Commission F |
|
| April 16, 2014 |
Relypsa, Inc. Announces Closing of Public Offering of Common Stock EX-99.1 Exhibit 99.1 NEWS RELEASE Contact: Sylvia Wheeler V.P. Investor Relations and Corporate Affairs 650-421-9504 [email protected] Relypsa, Inc. Announces Closing of Public Offering of Common Stock REDWOOD CITY, Calif., April 16, 2014 (GLOBE NEWSWIRE) — Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced the closing of its public offering of 4,130,611 shares of its common st |
|
| April 11, 2014 |
424B4 1 d692360d424b4.htm 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-194673 Registration No. 333-195198 3,591,836 Shares Common Stock We are offering 3,591,836 shares of our common stock in this offering. Our common stock is listed on The NASDAQ Global Select Market under the symbol “RLYP.” On April 10, 2014, the last reported sale price of our common stock was $ |
|
| April 10, 2014 |
Form S-1MEF As filed with the Securities and Exchange Commission on April 10, 2014 Registration No. |
|
| April 8, 2014 |
CORRESP 1 filename1.htm April 8, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Amy Reischauer Re: Relypsa, Inc. Registration Statement on Form S-1 (Registration No. 333-194673) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as |
|
| April 8, 2014 |
Table of Contents As filed with the Securities and Exchange Commission on April 8, 2014 Registration No. |
|
| April 8, 2014 |
[ ] Shares RELYPSA, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 [ ] Shares RELYPSA, INC. COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT [ ], 2014 [ ], 2014 Morgan Stanley & Co. LLC Merrill Lynch, Pierce, Fenner & Smith Incorporated Cowen and Company, LLC As Representatives of the several Underwriters listed in Schedule I to the Underwriting Agreement c/o Morgan Stanley & Co. LLC 1585 Broadway New York, NY 10036 c/o Merrill L |
|
| April 8, 2014 |
CORRESP Relypsa, Inc. 700 Saginaw Drive Redwood City, CA 94063 April 8, 2014 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Amy Reischauer Re: Relypsa, Inc. Registration Statement on Form S-1 (Registration No. 333-194673) Ladies and Gentlemen: In acco |
|
| April 1, 2014 |
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.1@94`.*S,'`T((LQ M0S$#0R,#-P/[/L&J$J1'JB.-K`N!A5^")]1`B#``)\*!'H-"F5N9'-T7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@ M,"!O8FH-/#PO0V]N=&5N |
|
| March 26, 2014 |
March 26, 2014 Via E-Mail Ronald A. Krasnow General Counsel and Senior Vice President Relypsa, Inc. 700 Saginaw Drive Redwood City, CA 94063 Re: Relypsa, Inc. Registration Statement on Form S-1 Filed March 19, 2014 File No. 333-194673 Dear Mr. Krasnow: We have limited our review of your registration statement to resolution of your pending confidential treatment request. We urge all persons who are |
|
| March 19, 2014 |
EX-10.6 Exhibit 10.6 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Execution copy CONFIDENTIAL Manufacturing and Supply Agreement BETWEEN LANXESS CORPORATION AND RELYPSA, INC. EFFECTIVE AS OF NOVEMBER 27, 2012 Execution copy CONFIDENTIAL TA |
|
| March 19, 2014 |
EX-10.10 Exhibit 10.10 RELYPSA, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope. The purpose of the Relypsa, Inc. 2013 Employee Stock Purchase Plan, as it may be amended from time to time, (the “Plan”) is to assist employees of Relypsa, Inc., a Delaware corporation, (the “Company”) and its Designated Subsidiaries in acquiring a |
|
| March 19, 2014 |
RELYPSA, INC. EMPLOYMENT AGREEMENT Exhibit 10.21 RELYPSA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?) is made and entered into by and between Mary Corbett (?Executive?) and Relypsa, Inc. (the ?Company?) (together referred to herein as the ?Parties?) as of the date of the last signature hereto. This Agreement supersedes in its entirety any agreement to which the Company is a party with respect to Executive? |
|
| March 19, 2014 |
Registration Statement - FORM S-1 Form S-1 Table of Contents As filed with the Securities and Exchange Commission on March 19, 2014 Registration No. |
|
| March 19, 2014 |
In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they constitute the Investment Banking Division (the "Investment Banking Division") and the Alternative Investments business (the "AI Business") and U.S. private client services |
|
| March 19, 2014 |
RLYP / Relypsa, Inc. / CREDIT SUISSE AG/ - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* Relypsa Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 759531106 (CUSIP Number) Calendar Year 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| March 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 19, 2014 |
RELYPSA, INC. 2013 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. EX-10.9(a) Exhibit 10.9(a) RELYPSA, INC. 2013 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Relypsa, Inc. 2013 Equity Incentive Award Plan (as it may be amended from time to time, the “Plan”) is to promote the success and enhance the value of Relypsa, Inc. (the “Company”) by linking the individual interests of the members of the Board, Employees, and Consultants to those of the |
